Loading market movers...

Sorafenib

Phase 3

00%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Apr '27

BAYRYPhase 2$55.5B

Sorafenib Phase 2 Est. Readout

Sorafenib• Ovarian Cancer30

Apr 2027~Confirmed

00%

Competitive Landscape

15 competitors in Ovarian Cancer

ZNTLazenosertib

AZNSaruparib (AZD5305)

View Full Landscape

Drug Information

Target Indication

Ovarian Cancer

Clinical Trial

Last updated: 8/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BAYRY

BAYER

Healthcare•Europe•NASDAQ

Related Pipeline

Cipro XR (Ciprofloxacin, BAYQ3939)Phase 3

Urinary Tract Infection

DabigatranPhase 3

Hematoma

bemdaneprocelPhase 3

Parkinsons Disease (PD)

D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IVPhase 3

Acute Coronary Syndrome

Finerenone (Kerendia, BAY94-8862)Phase 3

Chronic Kidney Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts